Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Takeuchi I
2nd Department of Internal Medicine, School of Medicine China University, Japan.
Atherosclerosis. 1988 Aug;72(2-3):205-11. doi: 10.1016/0021-9150(88)90082-2.
The hypolipidemic effect of a new HMG-CoA reductase inhibitor, pravastatin, was examined. The reductions of serum cholesterol and LDL-cholesterol were dose-dependent and significant differences were observed between placebo and 10 or 20 mg groups (P less than 0.01), and 10 and 20 mg (P less than 0.05) groups. The reduction rate of cholesterol after 8 weeks during medication was 16.1% in the 10 mg group, 20.5% in the 20 mg group compared to baseline serum cholesterol levels. LDL-cholesterol decreased by 23.9% in the 10 mg group, and 29.8% compared to baseline LDL-cholesterol in the 20 mg group. The lowering of total cholesterol was entirely attributed to a reduction in LDL-cholesterol.
研究了一种新型HMG-CoA还原酶抑制剂普伐他汀的降血脂作用。血清胆固醇和低密度脂蛋白胆固醇的降低呈剂量依赖性，安慰剂组与10毫克或20毫克组之间（P<0.01）以及10毫克和20毫克组之间（P<0.05）观察到显著差异。与基线血清胆固醇水平相比，用药8周后，10毫克组胆固醇降低率为16.1%，20毫克组为20.5%。10毫克组低密度脂蛋白胆固醇降低了23.9%，20毫克组与基线低密度脂蛋白胆固醇相比降低了29.8%。总胆固醇的降低完全归因于低密度脂蛋白胆固醇的降低。
